Today’s Research Reports on Ceapro, Eyecarrot Innovations, Hamilton Thorne and Hemostemix
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Ceapro Inc.
https://rdinvesting.com/news/?ticker=CZO.V
Eyecarrot Innovations Corp.
https://rdinvesting.com/news/?ticker=EYC.V
Hamilton Thorne Ltd.
https://rdinvesting.com/news/?ticker=HTL.V
Hemostemix Inc.
https://rdinvesting.com/news/?ticker=HEM.V
Ceapro's stock moved 1.82% lower Tuesday, to close the day at $0.54. The stock recorded a trading volume of 80,395 shares, which was above its three months average volume of 12,799 shares. In the last year, Ceapro's shares have traded in a range of 0.49 - 1.75. The stock is currently trading 69.14% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.57 is below its 200-day moving average of $0.58. Shares of Ceapro have fallen approximately 1.82 percent year-to-date.
Access RDI's Ceapro Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CZO.V
On Tuesday, shares of Eyecarrot Innovations recorded a trading volume of 89,000 shares, which was above the three months average volume of 34,413 shares. The stock ended the day 11.76% higher at 0.19. The share price has gained 90.00% from its 52-week low with a 52-week trading range of 0.10 - 0.25. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.17 is greater than its 200-day moving average of $0.15. Shares of Eyecarrot Innovations have gained approximately 26.67 percent year-to-date.
Access RDI's Eyecarrot Innovations Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EYC.V
Hamilton Thorne's stock moved 2.74% higher Tuesday, to close the day at $0.75. The stock recorded a trading volume of 5,046 shares, which was below its three months average volume of 85,143 shares. In the last year, Hamilton Thorne's shares have traded in a range of 0.55 - 1.05. The share price has gained 36.36% from its 52 week low. The company's shares are currently trading at their 200-day moving average. The stock's 50-day moving average of $0.78 is greater than its 200-day moving average of $0.75. Shares of the company are trading at a Price to Earnings ratio of 46.87. Shares of Hamilton Thorne have gained approximately 2.74 percent year-to-date.
Access RDI's Hamilton Thorne Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=HTL.V
On Tuesday, shares of Hemostemix recorded a trading volume of 102,000 shares, which was below the three months average volume of 166,998 shares. The stock ended the day flat at 0.06. The share price has gained 100.00% from its 52-week low with a 52-week trading range of 0.03 - 0.16. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.06 is below its 200-day moving average of $0.08. Shares of Hemostemix have fallen approximately 14.29 percent year-to-date.
Access RDI's Hemostemix Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HEM.V
Our Actionable Research on Ceapro Inc. (TSXV:CZO.V), Eyecarrot Innovations Corp. (TSXV:EYC.V), Hamilton Thorne Ltd. (TSXV:HTL.V) and Hemostemix Inc. (TSXV:HEM.V) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute
SOURCE: RDInvesting.com